Preleukemic TEL-AML1-positive clones at cell level of 10(-3) to 10(-4) do not persist into adulthood
- PMID: 17114960
- DOI: 10.1097/01.mph.0000243652.33561.0f
Preleukemic TEL-AML1-positive clones at cell level of 10(-3) to 10(-4) do not persist into adulthood
Abstract
The TEL-AML1 translocation, t(12;21)(p13;q22), is one of the most frequent genetic aberrations in childhood B-cell precursor acute lymphoblastic leukemia (ALL), where it occurs in 25% of all cases. In contrast, the translocation is seen in only 3% of adult ALL cases. Evidence suggests that the TEL-AML1 translocation occurs in utero in 1% of all newborn children at cell levels of 10 to 10. In this study, we explore the prevalence of TEL-AML1-positive cells in 2 cohorts of healthy blood donors by real-time and nested reverse transcription-polymerase chain reaction. Overall, TEL-AML1-positive cells were demonstrated in 10 of 2005 healthy donors, that is, a prevalence of 0.5% (95% confidence interval, 0.2-0.3%). The level of TEL-AML1-positive cells was estimated to 10 to 10. The observed prevalence of TEL-AML1-positive cells in healthy adults is of the same order of magnitude as the prevalence reported in healthy newborns, but the observed cell level of 10 to 10 is much lower. These data indicates that prenatal TEL-AML1 subclones does not persist throughout adult life at cell levels of 10 to 10. The findings are compatible with the risk of t(12;21)(p13;q22) ALL correlating with the total number of TEL-AML1-positive cells in peripheral blood in both childhood and adulthood.
Similar articles
-
Slower molecular response to treatment predicts poor outcome in patients with TEL/AML1 positive acute lymphoblastic leukemia: prospective real-time quantitative reverse transcriptase-polymerase chain reaction study.Cancer. 2003 Jan 1;97(1):105-13. doi: 10.1002/cncr.11043. Cancer. 2003. PMID: 12491511
-
Expression levels of TEL, AML1, and the fusion products TEL-AML1 and AML1-TEL versus drug sensitivity and clinical outcome in t(12;21)-positive pediatric acute lymphoblastic leukemia.Clin Cancer Res. 2005 Apr 15;11(8):2974-80. doi: 10.1158/1078-0432.CCR-04-1829. Clin Cancer Res. 2005. PMID: 15837750
-
Molecular quantification of response to therapy and remission status in TEL-AML1-positive childhood ALL by real-time reverse transcription polymerase chain reaction.Cancer Res. 2001 Mar 15;61(6):2517-22. Cancer Res. 2001. PMID: 11289124
-
[The role of TEL and AML1 genes in the pathogenesis of hematologic malignancies].Cas Lek Cesk. 2001 Mar 15;140(5):131-7. Cas Lek Cesk. 2001. PMID: 11347199 Review. Czech.
-
Molecular cytogenetics of t(12;21) (p13;q22).Leuk Lymphoma. 1996 Nov;23(5-6):459-65. doi: 10.3109/10428199609054854. Leuk Lymphoma. 1996. PMID: 9031076 Review.
Cited by
-
Generation of a Zebrafish Knock-In Model Recapitulating Childhood ETV6::RUNX1-Positive B-Cell Precursor Acute Lymphoblastic Leukemia.Cancers (Basel). 2023 Dec 13;15(24):5821. doi: 10.3390/cancers15245821. Cancers (Basel). 2023. PMID: 38136366 Free PMC article.
-
Insights into the prenatal origin of childhood acute lymphoblastic leukemia.Cancer Metastasis Rev. 2020 Mar;39(1):161-171. doi: 10.1007/s10555-019-09841-1. Cancer Metastasis Rev. 2020. PMID: 31902036 Free PMC article. Review.
-
Five percent of healthy newborns have an ETV6-RUNX1 fusion as revealed by DNA-based GIPFEL screening.Blood. 2018 Feb 15;131(7):821-826. doi: 10.1182/blood-2017-09-808402. Epub 2018 Jan 8. Blood. 2018. PMID: 29311095 Free PMC article. No abstract available.
-
Generation of a multi-antigen-directed immune response for durable control of acute lymphoblastic leukemia.Leukemia. 2018 Feb;32(2):539-542. doi: 10.1038/leu.2017.290. Epub 2017 Sep 19. Leukemia. 2018. PMID: 28924244 No abstract available.
-
The prenatal origins of cancer.Nat Rev Cancer. 2014 Apr;14(4):277-89. doi: 10.1038/nrc3679. Epub 2014 Mar 6. Nat Rev Cancer. 2014. PMID: 24599217 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
